Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
|Articles|September 1, 2002
Combination adapalene/clindamycin hastens, improves clearing of inflammatoryacne
Paris - Combination topical-antibiotic-plus-retinoid treatmentof inflammatory acne using adapalene 0.1 percent gel (Differin) with clindamycin1 percent lotion offers better efficacy and safety compared with clindamycin1 percent lotion alone, according to the results of a study presented atthe World Congress of Dermatology.
Advertisement
Advertisement
Related to this article
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
Genetic study links higher BMI to looking older, but causality stays unclear; Mendelian randomization flags shared signals and candidate genes needing validation.
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Dermatology Times is looking back on the top stories in dermatology from the month of September.
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Alopecia Areata Awareness Month: 2026 in Review
3
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
4
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
5